IT8340021A1 - Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprietà farmacologiche per degradazione chimica di eparina - Google Patents

Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprietà farmacologiche per degradazione chimica di eparina

Info

Publication number
IT8340021A1
IT8340021A1 IT1983A40021A IT4002183A IT8340021A1 IT 8340021 A1 IT8340021 A1 IT 8340021A1 IT 1983A40021 A IT1983A40021 A IT 1983A40021A IT 4002183 A IT4002183 A IT 4002183A IT 8340021 A1 IT8340021 A1 IT 8340021A1
Authority
IT
Italy
Prior art keywords
heparin
preparation
oligosaccharide fractions
pharmacological properties
chemical degradation
Prior art date
Application number
IT1983A40021A
Other languages
English (en)
Other versions
IT8340021A0 (it
IT1195497B (it
Original Assignee
Opocrin Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opocrin Spa filed Critical Opocrin Spa
Publication of IT8340021A0 publication Critical patent/IT8340021A0/it
Priority to IT40021/83A priority Critical patent/IT1195497B/it
Priority to AT84101701T priority patent/ATE26843T1/de
Priority to DE198484101701T priority patent/DE121067T1/de
Priority to DE8484101701T priority patent/DE3463386D1/de
Priority to EP84101701A priority patent/EP0121067B1/en
Priority to US06/582,933 priority patent/US4629699A/en
Priority to AU25093/84A priority patent/AU549885B2/en
Priority to ZA841520A priority patent/ZA841520B/xx
Priority to CA000448827A priority patent/CA1212942A/en
Priority to JP59044787A priority patent/JPS59187002A/ja
Publication of IT8340021A1 publication Critical patent/IT8340021A1/it
Priority to US06/921,332 priority patent/US4791195A/en
Priority to US07/247,154 priority patent/US4933326A/en
Application granted granted Critical
Publication of IT1195497B publication Critical patent/IT1195497B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Materials For Medical Uses (AREA)
IT40021/83A 1983-03-08 1983-03-08 Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina IT1195497B (it)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IT40021/83A IT1195497B (it) 1983-03-08 1983-03-08 Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
AT84101701T ATE26843T1 (de) 1983-03-08 1984-02-18 Verfahren zur herstellung von oligosaccharidfraktionen mit pharmakologischen eigenschaften durch chemische degradierung von heparin.
DE198484101701T DE121067T1 (de) 1983-03-08 1984-02-18 Verfahren zur herstellung von oligosaccharidfraktionen mit pharmakologischen eigenschaften durch chemische degradierung von heparin.
DE8484101701T DE3463386D1 (en) 1983-03-08 1984-02-18 Process for the preparation of oligosaccharide fractions having pharmacological properties by chemical degradation of heparin
EP84101701A EP0121067B1 (en) 1983-03-08 1984-02-18 Process for the preparation of oligosaccharide fractions having pharmacological properties by chemical degradation of heparin
US06/582,933 US4629699A (en) 1983-03-08 1984-02-23 Process for the preparation of oligosaccharide fractions by degradation of heparin
AU25093/84A AU549885B2 (en) 1983-03-08 1984-02-27 Heparin degradation via ascorbic acid, cupric acetate and hydrogen peroxide
ZA841520A ZA841520B (en) 1983-03-08 1984-02-29 Process for the preparation of oligosaccharide fractions having pharmacological properties by chemical degradation of heparin
CA000448827A CA1212942A (en) 1983-03-08 1984-03-05 Process for the preparation of oligosaccharide fractions having pharmaceutical properties by chemical degradation of heparin
JP59044787A JPS59187002A (ja) 1983-03-08 1984-03-07 薬理活性を有するオリゴ糖分画およびその製造法
US06/921,332 US4791195A (en) 1983-03-08 1986-10-21 Novel oligosaccharides having pharmacological properties by depolymerization of heparin
US07/247,154 US4933326A (en) 1983-03-08 1988-09-21 Oligosaccharides obtained by heparin depolymerization having antiatherosclerotic activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT40021/83A IT1195497B (it) 1983-03-08 1983-03-08 Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina

Publications (3)

Publication Number Publication Date
IT8340021A0 IT8340021A0 (it) 1983-03-08
IT8340021A1 true IT8340021A1 (it) 1984-09-08
IT1195497B IT1195497B (it) 1988-10-19

Family

ID=11246670

Family Applications (1)

Application Number Title Priority Date Filing Date
IT40021/83A IT1195497B (it) 1983-03-08 1983-03-08 Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina

Country Status (9)

Country Link
US (3) US4629699A (it)
EP (1) EP0121067B1 (it)
JP (1) JPS59187002A (it)
AT (1) ATE26843T1 (it)
AU (1) AU549885B2 (it)
CA (1) CA1212942A (it)
DE (2) DE121067T1 (it)
IT (1) IT1195497B (it)
ZA (1) ZA841520B (it)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1163772B (it) * 1983-07-13 1987-04-08 Baldacci Lab Spa Oligosaccaridi eterogenei complessabili ed alfa-idosani ad attivita' terapeutica, procedimento per la loro preparazione e relative composizioni farmaceutiche
IT1208509B (it) * 1985-03-13 1989-07-10 Mediolanum Farmaceutici Srl Processo per la produzione di eparan solfato e dermatan solfato naturali sostanzialmente puri eloro impiego farmaceutico.
IT1214609B (it) * 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
IT1213384B (it) * 1986-11-24 1989-12-20 Lab Derivati Organici Mediolan Processo per la preparazione controllata di gilcosaminoglicani a basso peso molecolare.
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
EP0337327A1 (en) * 1988-04-09 1989-10-18 Bioiberica, S.A. Process for the preparation of new oligosaccharide fractions by controlled chemical depolimerization of heparin
IT1234508B (it) * 1988-06-10 1992-05-19 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
IT1234826B (it) * 1989-01-30 1992-05-29 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US5519010A (en) * 1989-02-06 1996-05-21 Taiho Pharmaceutical Co., Ltd. Sulfated polysaccharide, pharmaceutically acceptable salt thereof, process for preparing same and medicament containing same as effective component
WO1991015217A1 (en) * 1990-04-06 1991-10-17 Washington University Anticoagulant oligosaccharides
IT1243987B (it) * 1990-10-29 1994-06-28 Derivati Organici Lab Procedimento per la preparazione di epossi-eparidi prodotti ottenuti ecomposizioni farmaceutiche che li contengono
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
GB9206291D0 (en) * 1992-03-23 1992-05-06 Cancer Res Campaign Tech Oligosaccharides having growth factor binding affinity
US5861382A (en) * 1992-05-01 1999-01-19 Yeda Research And Development Co. Ltd. Methods for regulation of active TNF-α
US6750207B1 (en) 1992-05-01 2004-06-15 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
EP0669827B1 (en) * 1992-11-10 2001-05-23 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
IT1264709B1 (it) * 1993-07-12 1996-10-04 Italfarmaco Spa Derivati eparinici ad attivita' antimetastatica
US6001820A (en) * 1995-03-31 1999-12-14 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
BR9713141A (pt) * 1996-11-27 2000-02-08 Rhone Poulenc Rorer Pharma Composição farmcêutica processo e kit para o tratamento ou a prevenção de um quadro fisiológico asociado com um distúrbio isquêmico relacionado com trombose e um paciente, uso de quantidades farmaceuticamente efetivas de um composto com atividade anti-xa e de um composto antagonista de agregação de plaquetas, produto contendo estes compostos, e, uso destes compostos.
CA2293595A1 (en) * 1997-06-06 1998-12-10 Hamilton Civic Hospitals Research Development, Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
AUPO888497A0 (en) * 1997-09-01 1997-09-25 Australian National University, The Use of sulfated oligosaccharides as inhibitors of cardiovascular disease
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
AUPO976897A0 (en) * 1997-10-14 1997-11-06 Australian National University, The Use of sulfated oligosaccharides in lowering blood triglyceride levels
US6235725B1 (en) 1998-10-30 2001-05-22 Baker Norton Pharmaceuticals, Inc. Methods and compositions for the prevention of tolerance to medications
EP1192187A1 (en) * 1999-06-30 2002-04-03 Hamilton Civic Hospitals Research Development, Inc. Heparin compositions that inhibit clot associated coagulation factors
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
CZ2003961A3 (cs) * 2000-09-08 2003-10-15 Hamilton Civic Hospitals Research Development, Inc. Farmaceutický prostředek k inhibici nebo prevenci tvorby či aktivity thrombinu
US7285536B2 (en) * 2001-12-05 2007-10-23 Yeda Research And Development Co., Ltd. Anti-cancer therapeutic compounds
JP4828795B2 (ja) 2002-03-11 2011-11-30 モメンタ ファーマシューティカルズ インコーポレイテッド 硫酸化多糖類の分析
US20040171819A1 (en) 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
US20050085478A1 (en) * 2003-08-22 2005-04-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
ITMI20042068A1 (it) * 2004-10-29 2005-01-29 Opocrin Spa Nuovo uso di eparine a bassissimo peso molecolare
ATE552004T1 (de) 2005-11-30 2012-04-15 Istituto G Ronzoni Oral verabreichbare heparinderivate
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
EP2205642B1 (en) 2007-11-02 2016-01-27 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
WO2010014909A1 (en) * 2008-08-01 2010-02-04 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
US8186278B2 (en) * 2008-08-04 2012-05-29 Industrial Design Fabrication & Installation, Inc. Gear switch for a conveyor assembly
EP2526122B1 (en) 2010-01-19 2020-06-10 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
WO2011130697A2 (en) 2010-04-16 2011-10-20 Momenta Pharmaceuticals, Inc. Tissue targeting
CN103096870B (zh) 2010-06-17 2017-04-19 动量制药公司 调节毛发生长的方法和组合物
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
CA2910837A1 (en) 2013-05-28 2014-12-04 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
CN106947004A (zh) * 2017-03-02 2017-07-14 浙江大学 一种低分子量肝素的制备方法
CN107090052A (zh) * 2017-05-16 2017-08-25 浙江大学 一种低分子量果胶的制备方法
CN110809474A (zh) * 2017-06-20 2020-02-18 加利福尼亚大学董事会 生物活性寡糖的生产
WO2022015794A1 (en) 2020-07-14 2022-01-20 Optimvia, Llc Methods for synthesizing non-anticoagulant heparan sulfate
WO2021007429A1 (en) 2019-07-09 2021-01-14 Optimvia Llc Methods for synthesizing anticoagulant polysaccharides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1083903B (it) * 1977-08-09 1985-05-25 Lobo Srl Oligo-eteropolisaccaridi con attivita' eparinosimili,procedimento per il loro ottenimento e relative composizioni terapeutiche
FR2440376A1 (fr) * 1978-11-06 1980-05-30 Choay Sa Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir
US4500519A (en) * 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
US4281108A (en) * 1980-01-28 1981-07-28 Hepar Industries, Inc. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained
JPS56120704A (en) * 1980-01-28 1981-09-22 Hepar Ind Inc Method of obtaining low molecular weight heparin having heightened pharmacologic property* product manufactured thereby and its use
US4351938A (en) * 1980-05-19 1982-09-28 Riker Laboratories, Inc. Anticoagulant substance

Also Published As

Publication number Publication date
DE3463386D1 (en) 1987-06-04
IT8340021A0 (it) 1983-03-08
AU2509384A (en) 1984-09-13
IT1195497B (it) 1988-10-19
US4933326A (en) 1990-06-12
DE121067T1 (de) 1985-01-17
EP0121067B1 (en) 1987-04-29
JPS59187002A (ja) 1984-10-24
EP0121067A1 (en) 1984-10-10
CA1212942A (en) 1986-10-21
ATE26843T1 (de) 1987-05-15
JPS6344765B2 (it) 1988-09-06
ZA841520B (en) 1984-10-31
AU549885B2 (en) 1986-02-20
US4629699A (en) 1986-12-16
US4791195A (en) 1988-12-13

Similar Documents

Publication Publication Date Title
IT8340021A1 (it) Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprietà farmacologiche per degradazione chimica di eparina
Gottschalk The chemistry and biology of sialic acids and related substances
FI88166B (fi) Bis-aldonsyraamider och foerfarande foer deras framstaellning
DE68917040T2 (de) Heparinderivate und Verfahren zu deren Herstellung.
DE3871637T2 (de) Pentasaccharide.
MARR et al. Molecular and genetic aspects of human blood-group Leb specificity
DE3379108D1 (en) Process for the organic synthesis of oligonucleotides containing galactosamin-uron-acid motives, oligosaccharides obtained and their biological applications
KR870006074A (ko) 고순도 아카르보스 및 그의 제조방법
DE3485680D1 (de) Gangliosid-derivate.
SI1082321T1 (en) Heterocyclic derivatives which inhibit factor xa
Foster et al. 14. Amino-sugars and related compounds. Part II. Observations on the acidic hydrolysis of derivatives of 2-amino-2-deoxy-D-glucose (D-glucosamine)
Veyrières Blood-group li-active oligosaccharides. Synthesis of a tetrasaccharide, a β-(1→ 3) dimer of N-acetyl-lactosamine
ES546783A0 (es) Procedimiento de preparacion de polisacaridos membranarios de origen bacteriano
Poletti et al. A Rational Approach to Heparin‐Related Fragments− Synthesis of Differently Sulfated Tetrasaccharides as Potential Ligands for Fibroblast Growth Factors
UA8020A1 (uk) Спосіб отримання 2,4-діхлор-5-фторбензойної кислоти
FI915570A0 (fi) Inklusionskomplex av 3 -morfolinosydnonimin eller dess salter eller dess tautomera isomerer, foerfarande foer deras framstaellning och farmaceutiska kompositioner innehaollande desamma.
YU21501A (sh) Novi derivati benzoilgvanidina sa svojstvima koja imaju prednost, postupak za njihovo pripremanje i njihova primena u pripremanju lekova
Anderson et al. Structural studies of the extracellular polysaccharide from Butyrivibrio fibrisolvens strain X6C61
Wolfrom et al. L-Iduronic acid in purified heparin
SU981322A1 (ru) Способ получени водорастворимого линейного полисахарида
ATE33496T1 (de) Verfahren zur herstellung von organischen oligosacchariden uebereinstimmend mit fragmenten von natuerlichen muco-polysacchariden, die erhaltenen oligosaccharide und ihre biologische verwendung.
JPS5573773A (en) Conductive treatment
Shibaev et al. Chemical-enzymatic synthesis of Salmonella serogroup E sub (1) O-specific polysaccharide.
SU1541218A1 (ru) Способ получения производных декстрана
ES402085A1 (es) Procedimiento para la obtencion de un sustituto del plasma,libre de pirogenos.